Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.2 EUR | +3.39% | +2.59% | -4.03% |
05-14 | BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 | CI |
05-09 | Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.03% | 17.89B | - | ||
+9.02% | 114B | B+ | ||
+11.42% | 104B | B+ | ||
-12.38% | 22.41B | B+ | ||
-1.05% | 22.28B | B | ||
-5.29% | 19.07B | A- | ||
-38.29% | 18B | A- | ||
+8.07% | 14.28B | C+ | ||
+35.06% | 12.55B | C+ | ||
-24.35% | 8.45B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BGNE Stock
- 49B Stock
- Ratings BeiGene, Ltd.